Disclosures for "Phase 1 Safety and Pharmacodynamic Results of VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Development for Thyroid Eye Disease (TED) ")
-
Dr. She has received personal compensation for serving as an employee of Viridian Therapeutics. Dr. She has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dianthus Therapeutics. Dr. She has stock in Viridian Therapeutics.
-
Dr. Katz has received personal compensation for serving as an employee of Viridian Therapeutics. Dr. Katz has received stock or an ownership interest from Viridian Therapeutics.
-
Mrs. Summerfelt has received personal compensation for serving as an employee of Viridian Therapeutics. An immediate family member of Mrs. Summerfelt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Viridian Therapeutics. Mrs. Summerfelt has stock in Viridian Therapeutics.
-
Dr. Oshaughnessy has received personal compensation for serving as an employee of viridian therapeutics. Dr. Oshaughnessy has stock in viridian therapeutics.
-
Mr. Dickinson has nothing to disclose.
-
Dr. Foster has received personal compensation for serving as an employee of Viridian Therapeutics.
-
Dr. Bedian has received personal compensation for serving as an employee of Viridian Therapeutics. Dr. Bedian has received personal compensation for serving as an employee of Dianthus Therapeutics. Dr. Bedian has stock in Viridian Therapeutics. Dr. Bedian has stock in Astria Therapeutics.